Apart from the achievement of a satisfactory glycemic profile and improvement of the insulin sensitivity pioglitazone use is known to be associated with the amelioration of dyslipidemia in patients with T2DM [3, 37]. This evidence concerns the gene INS and metabolic syndrome.